Author's abstract Ethical reasons are presented for requiring 1) that a proposal for a clinical trial should be accompanied by a thorough review of all previous trials that have examined the same and closely related questions, and 2) that a trial should be approved by a research ethics committee only if the investigator undertakes to register it in an appropriate register of clinical trials as soon as one exists.
Introduction
Important questions to be asked about a clinical trial include: 1) Why is the trial necessary, or worth doing? 2) Will the findings of the trial be made public? Both questions raise ethical issues, discussed below, which have implications for the work of ethics committees.
1) The need for systematic review A trial may be necessary to answer an important unanswered question. It may be that the question has been examined in previous trials, with inconclusive or conflicting results; or it may not have been addressed before. However, if the question has been clearly answered by previous trials, the gain from doing another may be negligible, and it would not be justified. A well known example is the use of a placebo in a condition for which a treatment of proven effectiveness exists. In such a case the use of a placebo is unacceptable, unless the condition is a trivial one.
It follows that a proposal for a trial should be accompanied by a thorough review of all previous trials that have examined the same and closely related questions. Only in the light of such a review can a sound opinion be given on whether the proposal is ethical.
2) Publication of the results
It is important that the evidence generated in well performed clinical trials is published, but much of it remains inaccessible. This under-reporting of research must be regarded as a form of scientific misconduct, because it creates a distortion in the publicly available evidence. It represents not only a waste of the resources used in the unreported work (patients' co-operation, investigators' skill, health facilities, time, money), but impedes the use&of effective treatment or the abandonment of ineffective treatment; it also requires otherwise avoidable subsequent research to correct the distortions. It is mainly investigators and commercial sponsors, rather than referees or joumal editors, who appear to be responsible for the under-reporting (1). Investigators, research ethics committees and funding agencies should all take steps to ensure that this form of scientific misconduct is minimised.
It may be unrealistic to expect all trials to be published, but their findings must be made accessible to anyone wishing to make a systematic review of the trials concemed with a particular problem. The first step towards this goal is to ensure that it is possible to obtain a complete listing of these trials, and the names and addresses of the people who have information about them. A simple way of achieving this would be to register all clinical trials at inception in a register (2) . Such registers already exist for trials in some areas of medicine. However, more systematic development of such registers is needed, both in Britain and in other countries. Ethics committees have important opportunities to foster these developments and to ensure that the necessary information is assembled efficiently. 
